Micro Cap Growth Fund
Daily price w/o sales charge as of 03/31/2026
$22.92
$1.22
YTD Returns w/o sales charge as of 03/31/2026
-0.04%
Please click here for performance current to the most recent quarter-end and month-end.
Summary
Summary
Fund Basicsas of 02/27/2026
- Total Net Assets
- $187.73 M
- Inception Date
- 08/28/2020
- Dividend Frequency
- Annually
- Fund Gross Expense Ratio
- 2.12%
- Fund Net Expense Ratio
- 2.12%
- Number of Holdings
- 79
- Minimum Initial Investment
- $1,500+
Fund Expense Ratio :
Gross 2.12%
Net 2.12%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 08/01/2010 |
|---|
| w/o sales charge | 3.79% | 25.13% | 11.83% | -1.62% | 16.37% | 10.36% |
| Lipper Category Avg. Small-Cap Growth Funds | 4.34% | 16.82% | 11.88% | 1.98% | 11.90% | - |
| Russell Microcap® Growth Index | 2.75% | 35.22% | 15.88% | -0.44% | 9.87% | - |
| w/ sales charge | 2.79% | 24.13% | 11.83% | -1.62% | 16.37% | 10.36% |
Fund Expense Ratio :
Gross 2.12%
Net 2.12%
Fund Expense Ratio :
Gross 2.12%
Net 2.12%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 08/01/2010 |
|---|
| w/o sales charge | 9.92% | 9.92% | 13.31% | 0.97% | 13.37% | 10.27% |
| Lipper Category Avg. Small-Cap Growth Funds | 8.15% | 8.15% | 13.21% | 2.52% | 10.17% | - |
| Russell Microcap® Growth Index | 21.84% | 21.84% | 17.46% | 2.81% | 7.82% | - |
| w/ sales charge | 8.92% | 8.92% | 13.31% | 0.97% | 13.37% | 10.27% |
Fund Expense Ratio :
Gross 2.12%
Net 2.12%
Past performance is not a reliable indicator or guarantee of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost.
TEN LARGEST HOLDINGS as of 02/27/2026View Portfolio
| Holding | Assets |
|---|---|
| Cogent Biosciences Inc | 3.8% |
| Celcuity Inc | 2.9% |
| Adaptive Biotechnologies Corp | 2.8% |
| Tarsus Pharmaceuticals Inc | 2.7% |
| Terns Pharmaceuticals Inc | 2.6% |
| Terawulf Inc | 2.5% |
| Mirum Pharmaceuticals Inc | 2.3% |
| Applied Digital Corp | 2.2% |
| TAT Technologies Ltd | 2.1% |
| Lincoln Educational Services Corp | 2.1% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Sector Allocationas of 02/27/2026View Portfolio
| Sector | Weighting |
|---|
| Sector | Weighting |
|---|---|
| Communication Services | |
| Real Estate | |
| Utilities | |
| Consumer Discretionary | |
| Consumer Staples | |
| Energy | |
| Financials | |
| Health Care | |
| Industrials | |
| Information Technology | |
| Materials |
INVESTMENT TEAM
Your Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 2.12%
Net 2.12%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 08/01/2010 |
|---|
| w/o sales charge | 3.79% | 25.13% | 11.83% | -1.62% | 16.37% | 10.36% |
| Lipper Category Avg. Small-Cap Growth Funds | 4.34% | 16.82% | 11.88% | 1.98% | 11.90% | - |
| Russell Microcap® Growth Index | 2.75% | 35.22% | 15.88% | -0.44% | 9.87% | - |
| w/ sales charge | 2.79% | 24.13% | 11.83% | -1.62% | 16.37% | 10.36% |
Fund Expense Ratio :
Gross 2.12%
Net 2.12%
Fund Expense Ratio :
Gross 2.12%
Net 2.12%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 08/01/2010 |
|---|
| w/o sales charge | 9.92% | 9.92% | 13.31% | 0.97% | 13.37% | 10.27% |
| Lipper Category Avg. Small-Cap Growth Funds | 8.15% | 8.15% | 13.21% | 2.52% | 10.17% | - |
| Russell Microcap® Growth Index | 21.84% | 21.84% | 17.46% | 2.81% | 7.82% | - |
| w/ sales charge | 8.92% | 8.92% | 13.31% | 0.97% | 13.37% | 10.27% |
Fund Expense Ratio :
Gross 2.12%
Net 2.12%
Past performance is not a reliable indicator or guarantee of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost.
| Year | Fund Returns | Russell Microcap® Growth Index |
|---|
| 2025 | 9.92% | 21.84% |
| 2024 | 26.04% | 21.91% |
| 2023 | 5.01% | 9.11% |
| 2022 | -29.80% | -29.76% |
| 2021 | 2.75% | 0.88% |
| 2020 | 77.90% | 40.13% |
| 2019 | 33.23% | 23.33% |
| 2018 | 1.83% | -14.18% |
| 2017 | 37.02% | 16.65% |
| 2016 | 1.04% | 6.86% |
| 2015 | -7.32% | - |
| 2014 | 9.74% | - |
| 2013 | 76.86% | - |
| 2012 | 1.59% | - |
| 2011 | -6.61% | - |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|
| 2026 | - | - | - | - |
| 2025 | -18.07% | 15.62% | 13.71% | 2.05% |
| 2024 | 7.49% | -0.06% | 6.64% | 10.02% |
| 2023 | 5.33% | 3.98% | -13.62% | 11.00% |
| 2022 | -17.42% | -22.71% | 8.03% | 1.81% |
| 2021 | 12.08% | -0.29% | -9.62% | 1.72% |
| 2020 | -24.47% | 47.31% | 17.25% | 36.36% |
| 2019 | 22.33% | 7.20% | -14.11% | 18.30% |
| 2018 | 5.07% | 15.49% | 9.76% | -23.55% |
| 2017 | 8.70% | 7.90% | 13.35% | 3.06% |
| 2016 | -13.88% | 5.67% | 14.28% | -2.86% |
| 2015 | 7.07% | 3.87% | -16.51% | -0.19% |
| 2014 | 7.62% | -6.73% | -6.83% | 17.34% |
| 2013 | 21.51% | 14.77% | 17.00% | 8.39% |
| 2012 | 17.46% | -9.89% | 1.07% | -5.03% |
| 2011 | 4.58% | -0.03% | -22.09% | 14.64% |
Performance is shown for each quarter and each calendar year. Past performance is no guarantee of future results.
NAV Historical Prices
| Date | Net Asset Value |
|---|
Portfolio
Portfolio
| Holding | Sector | Assets |
|---|
| Cogent Biosciences Inc | Health Care | 3.8% |
| Celcuity Inc | Health Care | 2.9% |
| Adaptive Biotechnologies Corp | Health Care | 2.8% |
| Tarsus Pharmaceuticals Inc | Health Care | 2.7% |
| Terns Pharmaceuticals Inc | Health Care | 2.6% |
| Terawulf Inc | Information Technology | 2.5% |
| Mirum Pharmaceuticals Inc | Health Care | 2.3% |
| Applied Digital Corp | Information Technology | 2.2% |
| TAT Technologies Ltd | Industrials | 2.1% |
| Lincoln Educational Services Corp | Consumer Discretionary | 2.1% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
| Holding | Sector | Assets |
|---|
| Cogent Biosciences Inc | Health Care | 3.8% |
| Celcuity Inc | Health Care | 2.9% |
| Adaptive Biotechnologies Corp | Health Care | 2.8% |
| Tarsus Pharmaceuticals Inc | Health Care | 2.7% |
| Terns Pharmaceuticals Inc | Health Care | 2.6% |
| Terawulf Inc | Information Technology | 2.5% |
| Mirum Pharmaceuticals Inc | Health Care | 2.3% |
| Applied Digital Corp | Information Technology | 2.2% |
| TAT Technologies Ltd | Industrials | 2.1% |
| Lincoln Educational Services Corp | Consumer Discretionary | 2.1% |
| Sterling Infrastructure Inc | Industrials | 2.1% |
| Cardinal Infrastructure Group Inc | Industrials | 2.0% |
| Bel Fuse Inc | Information Technology | 2.0% |
| Mercury Systems Inc | Industrials | 1.9% |
| VSE Corp | Industrials | 1.9% |
| Willdan Group Inc | Industrials | 1.9% |
| Legence Corp | Industrials | 1.8% |
| Vita Coco Co Inc/The | Consumer Staples | 1.8% |
| CECO Environmental Corp | Industrials | 1.8% |
| OSI Systems Inc | Information Technology | 1.8% |
| Universal Technical Institute Inc | Consumer Discretionary | 1.7% |
| Lindblad Expeditions Holdings Inc | Consumer Discretionary | 1.6% |
| Nektar Therapeutics | Health Care | 1.6% |
| PTC Therapeutics Inc | Health Care | 1.5% |
| Sphere Entertainment Co | Communication Services | 1.5% |
| Praxis Precision Medicines Inc | Health Care | 1.5% |
| IMAX Corp | Communication Services | 1.5% |
| Standex International Corp | Industrials | 1.5% |
| CG oncology Inc | Health Care | 1.4% |
| Mineralys Therapeutics Inc | Health Care | 1.3% |
| AAR Corp | Industrials | 1.3% |
| Miami International Holdings Inc | Financials | 1.2% |
| Piper Sandler Cos | Financials | 1.2% |
| nLight Inc | Information Technology | 1.2% |
| 10X Genomics Inc | Health Care | 1.1% |
| ORIC Pharmaceuticals Inc | Health Care | 1.1% |
| TransMedics Group Inc | Health Care | 1.1% |
| Chefs' Warehouse Inc/The | Consumer Staples | 1.1% |
| Fastly Inc | Information Technology | 1.0% |
| Xometry Inc | Industrials | 1.0% |
| Aehr Test Systems | Information Technology | 1.0% |
| Primoris Services Corp | Industrials | 1.0% |
| Artivion Inc | Health Care | 1.0% |
| Pattern Group Inc | Consumer Discretionary | 1.0% |
| Gilat Satellite Networks Ltd | Information Technology | 1.0% |
| Calix Inc | Information Technology | 0.9% |
| BlackSky Technology Inc | Industrials | 0.9% |
| Rhythm Pharmaceuticals Inc | Health Care | 0.9% |
| Ouster Inc | Information Technology | 0.9% |
| Turning Point Brands Inc | Consumer Staples | 0.8% |
| Paymentus Holdings Inc | Financials | 0.8% |
| Dianthus Therapeutics Inc | Health Care | 0.8% |
| StoneX Group Inc | Financials | 0.8% |
| Navan Inc | Consumer Discretionary | 0.8% |
| Newamsterdam Pharma Co NV | Health Care | 0.7% |
| Warby Parker Inc | Consumer Discretionary | 0.7% |
| Mama's Creations Inc | Consumer Staples | 0.7% |
| Argan Inc | Industrials | 0.7% |
| Twist Bioscience Corp | Health Care | 0.7% |
| HeartFlow Inc | Health Care | 0.7% |
| Innodata Inc | Industrials | 0.7% |
| Ambarella Inc | Information Technology | 0.7% |
| GeneDx Holdings Corp | Health Care | 0.7% |
| Kestra Medical Technologies Ltd | Health Care | 0.7% |
| Red Violet Inc | Information Technology | 0.6% |
| Hinge Health Inc | Health Care | 0.5% |
| Dave Inc | Financials | 0.5% |
| Billiontoone Inc | Health Care | 0.5% |
| Forte Biosciences Inc | Health Care | 0.5% |
| Neogen Corp | Health Care | 0.5% |
| Centrus Energy Corp | Energy | 0.5% |
| Immunocore Holdings PLC | Health Care | 0.5% |
| York Space Systems Inc | Industrials | 0.5% |
| Cipher Digital Inc | Information Technology | 0.5% |
| Ceribell Inc | Health Care | 0.4% |
| Transcat Inc | Industrials | 0.4% |
| Zeta Global Holdings Corp | Information Technology | 0.4% |
| Neptune Insurance Holdings Inc | Financials | 0.3% |
| Arcellx Inc | Health Care | 0.3% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Sector Allocationas of 02/27/2026
| Sector | Weighting | Fund Change from Previous Quarter |
|---|
| Sector | Weighting | Fund Change from Previous Quarter |
|---|---|---|
| Communication Services |
1.2%
|
|
| Real Estate | 0.0% | |
| Utilities | 0.0% | |
| Consumer Discretionary |
1.7%
|
|
| Consumer Staples |
1.5%
|
|
| Energy |
 1.5%
|
|
| Financials |
1.2%
|
|
| Health Care |
2.8%
|
|
| Industrials |
1.1%
|
|
| Information Technology |
0.8%
|
|
| Materials | 0.0% |
Portfolio Details as of 02/27/2026
- Total Net Assets
- $187.73 M
- Number of Holdings
- 79
- Weighted Average Market Cap.
- 3.8 B
- P/B Ratio
- 6.4x
- P/E Ratio
- 37.1x
To view definitions for the above Portfolio Details, Click here.
P/B Ratio - A ratio that helps determine whether a stock is undervalued or overvalued. It is calculated by dividing a stock's price per share by its book value per share. The result is based upon a weighted average of the securities held in the fund.
P/E Ratio - Is the weighted average of each holding's P/E ratio (price of a stock divided by its earnings per share). The result is based upon a weighted average of the securities held in the fund.
Weighted Average Market Cap - The average market capitalization of all companies held in the portfolio with each company weighted according to its percent held in the portfolio. The result is based upon a weighted average of the securities held in the fund.
Dividends & Cap Gains
Dividends & Cap Gains
Upcoming Dividend Payment Dates
This section lists all anticipated Income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.
| Record Date | Ex-Dividend Date | Reinvest & Payable Date |
|---|---|---|
| 11/23/2026 | 11/24/2026 | 11/24/2026 |
Capital Gains Distributions
| Record Date | Reinvest & Payable Date | Long-term | Short-term * | Total | Reinvest Price |
|---|---|---|---|---|---|
| 11/23/2020 | 11/24/2020 | $2.8043 | $2.2741 | $5.0784 | $18.85 |
Taxed as ordinary income
Lord Abbett does not provide tax advice. It is strongly recommended that you discuss the impact of dividends and distributions with your tax advisor.
Fees & Expenses
Fees & Expenses
Expense Ratioas of 02/28/2026
| Fund Gross Expense Ratio | 2.12% |
| Fund Net Expense Ratio | 2.12% |
Fund Documents
Fund Documents
|
0Documents selected
|
||||
|---|---|---|---|---|
|
Portfolio Holdings 1Q
Publish Date:11/03/2015
|
||||
|
Portfolio Holdings 3Q
Publish Date:11/03/2015
|
||||
|
Summary Prospectus
Publish Date:11/03/2015
|
||||
|
Statutory Prospectus
Publish Date:11/03/2015
|
||||
|
SAI
Publish Date:11/03/2015
|
||||
|
Annual Financial Statements and Other Information *
Publish Date:11/03/2015
|
||||
|
2025 Annual Tailored Shareholder Report
Publish Date:11/03/2015
|
||||
|
2025 Semi-Annual Tailored Shareholder Report
Publish Date:11/03/2015
|
||||
|
Semi-Annual Financial Statements and Other Information *
Publish Date:11/03/2015
|
||||
|
Fact Sheet
Publish Date:11/03/2015
|